1. Home
  2. JONE vs ABEO Comparison

JONE vs ABEO Comparison

Compare JONE & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jones Ventures INTL Acquisition1 Corp Class A Ordinary Shares

JONE

Jones Ventures INTL Acquisition1 Corp Class A Ordinary Shares

N/A

Current Price

$9.86

Market Cap

282.0M

Sector

Finance

ML Signal

N/A

Logo Abeona Therapeutics Inc.

ABEO

Abeona Therapeutics Inc.

N/A

Current Price

$2.47

Market Cap

282.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JONE
ABEO
Founded
2021
1974
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
282.0M
282.5M
IPO Year
2026
2005

Fundamental Metrics

Financial Performance
Metric
JONE
ABEO
Price
$9.86
$2.47
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $15.56
AVG Volume (30 Days)
80.6K
★ 2.1M
Earning Date
N/A
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 165.16
EPS
★ N/A
N/A
Revenue
N/A
★ $2,998,000.00
Revenue This Year
N/A
$675.42
Revenue Next Year
N/A
$126.99
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 258.18
52 Week Low
$9.80
$2.09
52 Week High
$9.92
$7.65

Technical Indicators

Market Signals
Indicator
JONE
ABEO
Relative Strength Index (RSI) 56.13 27.45
Support Level $9.81 N/A
Resistance Level $9.92 $5.77
Average True Range (ATR) 0.00 0.33
MACD 0.00 -0.05
Stochastic Oscillator 50.00 16.27

Price Performance

Historical Comparison
JONE
ABEO

About JONE Jones Ventures INTL Acquisition1 Corp Class A Ordinary Shares

Jones Ventures INTL Acquisition1 Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.

Share on Social Networks: